Astrazeneca annual capital expenditures (capex)
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Capital Expenditures (CapEx) Growth & History (AZN)
Astrazeneca's capital expenditures (capex) was $2.81B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.81B | $886.0M | +46.05% |
| 2024 | 2024-12-31 | $1.92B | $563.0M | +41.37% |
| 2023 | 2023-12-31 | $1.36B | $270.0M | +24.75% |
| 2022 | 2022-12-31 | $1.09B | $0 | 0.00% |
| 2021 | 2021-12-31 | $1.09B | $130.0M | +13.53% |
| 2020 | 2020-12-31 | $961.0M | −$18.0M | −1.84% |
| 2019 | 2019-12-31 | $979.0M | −$64.0M | −6.14% |
| 2018 | 2018-12-31 | $1.04B | −$283.0M | −21.34% |
| 2017 | 2017-12-31 | $1.33B | −$120.0M | −8.30% |
| 2016 | 2016-12-31 | $1.45B | $118.0M | +8.89% |
| 2015 | 2015-12-31 | $1.33B | — | — |
Astrazeneca quarterly capital expenditures (capex)
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.10B | $1.18B | +61.47% |
| Q1 2026 | 2026-03-31 | $1.54B | — | — |
| Q4 2025 | 2025-12-31 | $1.29B | — | — |
| Q3 2025 | 2025-09-30 | $1.73B | — | — |
| Q2 2025 | 2025-06-30 | $1.92B | — | — |
Astrazeneca capital expenditures (capex) trends
Over the last five fiscal years, Astrazeneca's capital expenditures (capex) increased from $961.0M to $2.81B, a change of $1.85B. The latest reported quarter, Q2 2026, shows $3.10B.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...